ANEUVO

Company overview

ANEUVO is a Los Angeles bioelectronic medical device company founded in 2016 by Yi-Kai Lo and Wentai Liu. The company develops noninvasive neuromodulation technology for neurological injuries and disabling conditions.

Its ExaStim Stimulation System combines a portable stimulator, ReCure multi-electrode pad and software-based programming. In the United States, the cleared indication is improvement of hand sensation and strength in adults aged 18 to 75 with chronic deficits from incomplete spinal cord injury, alongside functional task practice.

ExaStim has FDA 510(k) clearance and CE Mark certification, with commercial activity in the United States and Europe. ANEUVO announced a $22 million Series C financing in March 2026 to support manufacturing, regulatory work and commercial expansion.

^{[1][2][3][5][6][7][8]}

Products & regulatory status How does MedTechIndex get this information?

Summary

FDA cleared ExaStim and its ReCure electrode pads under K252893 on March 27, 2026. The U.S. indication addresses hand sensation and strength after incomplete spinal cord injury when used with functional task practice. ^[4][5]

Regulatory snapshot How to read this snapshot

U.S. FDA

1+

510(k) clearances

—

De Novo grants

—

PMA approvals

—

Recall events

Latest recorded source review: 2026-11-02.

Scope: selected product families.

Commercial portfolio snapshot

Documented commercial product families.

Transcutaneous spinal stimulation system

ExaStim Stimulation System ↗

Portable transcutaneous spinal stimulation system with a ReCure multi-electrode pad and clinician programming software. FDA-cleared to improve hand sensation and strength in adults aged 18–75 with chronic deficits from incomplete spinal cord injury, when combined with functional task practice. ^[3][4][5][6]

FDA 510(k) cleared; commercially offered in the U.S. and Europe

FDA 510(k) cleared; commercially offered in the U.S. and Europe